Eli Lilly says experimental drug slows Alzheimer's worsening

FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. The company said Wednesday, May 3, 2023, that its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. WASHINGTON — — Eli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study.

The drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer’s. Donanemab also comes with that risk. Lilly said in its study, the brain side effects caused the deaths of two participants and a third also died after a serious case.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly's Alzheimer's drug donanemab slows cognitive decline: trialAn experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
Source: BusinessInsider - 🏆 729. / 51 Read more »

Eli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical trialDonanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.
Source: CNBC - 🏆 12. / 72 Read more »

Lilly drug slows Alzheimer's progression by 35% in trialAn experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a second effective treatment for the brain-wasting disease.
Source: Reuters - 🏆 2. / 97 Read more »